InnovAge - INNV Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InnovAge in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INNV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INNV, but not buy additional shares or sell existing shares.
View INNV analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12-month price targets for InnovAge's stock. Their INNV share price forecasts range from $3.90 to $8.00. On average, they predict the company's stock price to reach $5.98 in the next twelve months. This suggests that the stock has a possible downside of 20.7%.
View analysts price targets for INNV or view top-rated stocks among Wall Street analysts.

InnovAge's stock was trading at $7.18 on January 1st, 2023. Since then, INNV shares have increased by 5.0% and is now trading at $7.54.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our INNV earnings forecast.

InnovAge Holding Corp. (OTCMKTS:INNV) issued its earnings results on Tuesday, November, 8th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.06. The company earned $171.22 million during the quarter, compared to analysts' expectations of $173.04 million. InnovAge had a negative net margin of 3.92% and a negative trailing twelve-month return on equity of 6.79%.

Based on aggregate information from My MarketBeat watchlists, some companies that other InnovAge investors own include EEStor Co. (ESU.V) (ESU), Antares Pharma (ATRS), Federal National Mortgage Association (FNMA), Medicines (MDCO), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), Aytu BioPharma (AYTU), NVIDIA (NVDA) and Pacific Premier Bancorp (PPBI).

InnovAge trades on the OTCMKTS under the ticker symbol "INNV."

InnovAge's stock is owned by many different institutional and retail investors. Top institutional investors include Cambiar Investors LLC (0.23%), Strs Ohio (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Edward Moore Jr Kennedy, Maureen Hewitt and Thomas Scully.
View institutional ownership trends.

Shares of INNV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INNV stock can currently be purchased for approximately $7.54.

InnovAge (OTCMKTS:INNV) has a market capitalization of $1.02 billion and generates $698.64 million in revenue each year. The company earns $-6,520,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

The company employs 2,000 workers across the globe.

InnovAge's mailing address is 8845 Rehco Road, San Diego CA, 92121. The official website for the company is www.innovuspharma.com. The company can be reached via phone at 844-803-8745 or via email at ir@innovuspharma.com.